Biotech Stocks To Consider - May 30th

Veeva Systems, AbbVie, Thermo Fisher Scientific, Alnylam Pharmaceuticals, GSK, Vertex Pharmaceuticals, and Danaher are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies whose primary business involves research, development, and commercialization of healthcare products based on biological processes—such as drugs, therapies, and diagnostic tools derived from living organisms. Their market value often hinges on clinical-trial outcomes, regulatory approvals, and scientific breakthroughs, making them more volatile than many other sectors. Investors in biotech stocks typically seek growth potential linked to innovative treatments but must also be prepared for higher risk. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Veeva Systems (VEEV)

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

Shares of NYSE VEEV traded down $2.42 during mid-day trading on Friday, hitting $276.62. 1,202,529 shares of the company traded hands, compared to its average volume of 1,141,317. Veeva Systems has a 1 year low of $170.25 and a 1 year high of $285.70. The stock has a market capitalization of $45.00 billion, a price-to-earnings ratio of 68.36, a PEG ratio of 1.89 and a beta of 0.96. The business has a 50 day moving average of $229.69 and a two-hundred day moving average of $227.56.

Read Our Latest Research Report on VEEV

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

AbbVie stock traded down $0.60 during mid-day trading on Friday, hitting $185.02. The company's stock had a trading volume of 1,574,668 shares, compared to its average volume of 6,233,772. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. AbbVie has a 52-week low of $153.58 and a 52-week high of $218.66. The firm's 50 day moving average is $186.28 and its 200 day moving average is $186.16. The company has a market cap of $326.83 billion, a PE ratio of 77.13, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56.

Read Our Latest Research Report on ABBV

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

TMO stock traded up $0.08 during mid-day trading on Friday, hitting $403.83. The stock had a trading volume of 573,502 shares, compared to its average volume of 1,874,460. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $152.44 billion, a price-to-earnings ratio of 24.48, a PEG ratio of 2.99 and a beta of 0.82. The company has a fifty day moving average of $433.07 and a 200 day moving average of $501.01. Thermo Fisher Scientific has a 1-year low of $390.50 and a 1-year high of $627.88.

Read Our Latest Research Report on TMO

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Shares of NASDAQ ALNY traded up $10.47 during mid-day trading on Friday, reaching $303.37. 743,342 shares of the company traded hands, compared to its average volume of 919,436. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a market cap of $39.56 billion, a PE ratio of -139.59 and a beta of 0.17. The company's fifty day moving average is $259.91 and its two-hundred day moving average is $254.83. Alnylam Pharmaceuticals has a fifty-two week low of $146.79 and a fifty-two week high of $304.39.

Read Our Latest Research Report on ALNY

GSK (GSK)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Shares of NYSE GSK traded up $0.94 during mid-day trading on Friday, reaching $40.94. 4,354,442 shares of the company traded hands, compared to its average volume of 4,848,630. The stock has a market cap of $84.46 billion, a PE ratio of 25.75, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company's fifty day moving average is $37.29 and its two-hundred day moving average is $36.11. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.01.

Read Our Latest Research Report on GSK

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

VRTX traded down $5.01 during midday trading on Friday, reaching $442.08. The company's stock had a trading volume of 380,977 shares, compared to its average volume of 1,414,021. The stock has a market cap of $113.52 billion, a P/E ratio of -200.93, a PEG ratio of 2.11 and a beta of 0.51. The company has a fifty day simple moving average of $470.99 and a 200 day simple moving average of $461.47. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88.

Read Our Latest Research Report on VRTX

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of NYSE:DHR traded down $0.78 during trading on Friday, hitting $189.69. 717,897 shares of the stock were exchanged, compared to its average volume of 3,462,288. Danaher has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a market capitalization of $135.76 billion, a price-to-earnings ratio of 35.97, a price-to-earnings-growth ratio of 2.66 and a beta of 0.80. The company's fifty day simple moving average is $193.18 and its 200-day simple moving average is $214.13. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Read Our Latest Research Report on DHR